Q3 2024 EPS Estimates for MDxHealth SA Cut by Analyst (NASDAQ:MDXH)

MDxHealth SA (NASDAQ:MDXH) – Analysts at William Blair dropped their Q3 2024 earnings estimates for MDxHealth in a report released on Thursday, August 22nd. William Blair analyst A. Brackmann now anticipates that the company will earn ($0.26) per share for the quarter, down from their prior forecast of ($0.20). The consensus estimate for MDxHealth’s current full-year earnings is ($1.00) per share. William Blair also issued estimates for MDxHealth’s Q4 2024 earnings at ($0.23) EPS, FY2024 earnings at ($1.11) EPS, Q1 2025 earnings at ($0.24) EPS, Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and FY2025 earnings at ($0.71) EPS.

MDxHealth Stock Performance

NASDAQ:MDXH opened at $2.87 on Monday. MDxHealth has a 1-year low of $2.15 and a 1-year high of $4.64. The company’s fifty day moving average price is $2.71 and its 200-day moving average price is $2.83. The company has a current ratio of 1.69, a quick ratio of 1.53 and a debt-to-equity ratio of 5.43.

Institutional Trading of MDxHealth

A hedge fund recently bought a new stake in MDxHealth stock. FAS Wealth Partners Inc. acquired a new position in MDxHealth SA (NASDAQ:MDXH) during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 16,325 shares of the company’s stock, valued at approximately $42,000.

About MDxHealth

MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.